As the year comes to a close, Adalvo reflects on the 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐦𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞𝐬 attained by our team. Wishing all our esteemed colleagues, partners, and friends a 𝐇𝐚𝐩𝐩𝐲 𝐍𝐞𝐰 𝐘𝐞𝐚𝐫! May the approaching year be filled with promising opportunities and exciting ventures. #Adalvo #AlwaysOnTarget
Adalvo
Pharmaceutical Manufacturing
We're driven by our passion for relentless commitment to the partner network we serve.
About us
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 100 countries and for over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners. With headquarters in Malta, the company presence in more than 15 countries such as Switzerland, UK, Netherlands, Spain, Iceland, Austria, Romania, Hungary, Bulgaria, Turkey, Italy, Czech Republic, Uruguay, Slovenia and India. At Adalvo, we know that our partners like to be bigger, better and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals. We take pride in our ability to help its partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion to making a difference for partners. The company’s purpose driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
- Website
-
http://www.adalvo.com
External link for Adalvo
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- San Gwann
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
Malta Life Science Park
Building 1 Level 4
San Gwann, SGN 3000, MT
Employees at Adalvo
-
Sofia Ferreira
Sales Director /Country Manager/International Commercial Manager/Head of sales
-
Dr. Arti Banerjee
PhD|Director, Project Management at ADALVO|Ex Mylan,DRL& Zydus|Significant experience in R&D projects, strategic partnerships etc.
-
Luca Strusi
VP R&D 3rd Parties
-
Kirsten Orland
Responsible Person at Adalvo
Updates
-
Adalvo extends warm 𝐒𝐞𝐚𝐬𝐨𝐧'𝐬 𝐆𝐫𝐞𝐞𝐭𝐢𝐧𝐠𝐬 𝐚𝐧𝐝 𝐡𝐞𝐚𝐫𝐭𝐟𝐞𝐥𝐭 𝐰𝐢𝐬𝐡𝐞𝐬 𝐟𝐨𝐫 𝐚 𝐇𝐚𝐩𝐩𝐲 𝐍𝐞𝐰 𝐘𝐞𝐚𝐫 to our partners, colleagues, and friends. Our diverse hive spread across the globe, united to 𝐬𝐡𝐚𝐫𝐞 𝐭𝐡𝐞𝐬𝐞 𝐟𝐞𝐬𝐭𝐢𝐯𝐞 𝐦𝐨𝐦𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐲𝐨𝐮. May the coming year bring 𝐰𝐚𝐫𝐦𝐭𝐡, 𝐩𝐫𝐨𝐬𝐩𝐞𝐫𝐢𝐭𝐲, 𝐚𝐧𝐝 𝐬𝐡𝐚𝐫𝐞𝐝 𝐬𝐮𝐜𝐜𝐞𝐬𝐬. Thank you for being a part of the Adalvo journey. #Adalvo #AlwaysOnTarget #SeasonsGreetings
-
Adalvo’𝐬 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫 𝐨𝐟 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭, Bruno Alves and 𝐒𝐚𝐥𝐞𝐬 𝐚𝐧𝐝 𝐏𝐫𝐨𝐣𝐞𝐜𝐭 𝐌𝐚𝐧𝐚𝐠𝐞𝐫, Daria Koloskova will be at the Arab Health Exhibition this January. Will you be there too? 𝐂𝐨𝐧𝐧𝐞𝐜𝐭 𝐰𝐢𝐭𝐡 𝐁𝐫𝐮𝐧𝐨 𝐚𝐧𝐝 𝐃𝐚𝐫𝐢𝐚 to explore 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬, upcoming launches, and insights into the latest trends shaping the pharmaceutical landscape. #Adalvo #AlwaysOnTarget #ArabHealth #MENA
-
Adalvo announces the launch of the 𝐟𝐢𝐫𝐬𝐭-𝐞𝐯𝐞𝐫 𝐠𝐞𝐧𝐞𝐫𝐢𝐜 𝐯𝐞𝐫𝐬𝐢𝐨𝐧 𝐨𝐟 𝐍𝐢𝐭𝐫𝐨𝐟𝐮𝐫𝐚𝐧𝐭𝐨𝐢𝐧 to the UK, in collaboration with CNX Therapeutics. Having 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐞𝐝 𝐭𝐡𝐢𝐬 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐢𝐧-𝐡𝐨𝐮𝐬𝐞, Adalvo are very proud to bring the 𝟏𝐬𝐭 𝐠𝐞𝐧𝐞𝐫𝐢𝐜 𝐨𝐟 𝐍𝐢𝐭𝐫𝐨𝐟𝐮𝐫𝐚𝐧𝐭𝐨𝐢𝐧 𝐄𝐑 to the UK market, even though the patent has expired in 2007. Click here to find out more - https://lnkd.in/e8PfFRQQ #Adalvo #CNXTherapeutics #AlwaysOnTarget #Nitrofurantoin
-
Adalvo’s team will be attending the J.P. Morgan 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 from 𝟏𝟑 𝐭𝐨 𝟏𝟔 𝐉𝐚𝐧𝐮𝐚𝐫𝐲 𝟐𝟎𝟐𝟓 𝐢𝐧 𝐒𝐚𝐧 𝐅𝐫𝐚𝐧𝐜𝐢𝐬𝐜𝐨. Representing the company will be ANIL OKAY, 𝐂𝐄𝐎 𝐚𝐧𝐝 𝐅𝐨𝐮𝐧𝐝𝐞𝐫; Arni Baldursson, 𝐒𝐕𝐏 𝐆𝐥𝐨𝐛𝐚𝐥 𝐂𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 & 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭; and Istvan Tisler, 𝐒𝐕𝐏 𝐏𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 & 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 To arrange a meeting with our team, please 𝐜𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬 𝐝𝐢𝐫𝐞𝐜𝐭𝐥𝐲. #Adalvo #AlwaysOnTarget #JPMorgan #HealthcareConfrence #SanFrancisco
-
Adalvo have successfully launched the 𝐟𝐢𝐫𝐬𝐭-𝐭𝐨-𝐦𝐚𝐫𝐤𝐞𝐭 𝐋𝐢𝐬𝐝𝐞𝐱𝐚𝐦𝐟𝐞𝐭𝐚𝐦𝐢𝐧𝐞 𝐎𝐫𝐚𝐥 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐢𝐧 𝐆𝐞𝐫𝐦𝐚𝐧𝐲, achieved in collaboration with our strategic partner, Aristo Pharma GmbH, and co-developers, 𝐋𝐚𝐛𝐨𝐦𝐞𝐝 and 𝐏𝐡𝐚𝐫𝐦𝐚𝐝𝐚𝐭𝐚. The formulation is protected by a granted European Patent. The launch takes place following the 𝐫𝐞𝐯𝐨𝐜𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐒𝐏𝐂 𝐛𝐲 𝐭𝐡𝐞 𝐅𝐞𝐝𝐞𝐫𝐚𝐥 𝐏𝐚𝐭𝐞𝐧𝐭 𝐂𝐨𝐮𝐫𝐭 (appeal pending), and reflects 𝐀𝐝𝐚𝐥𝐯𝐨’𝐬 𝐟𝐨𝐜𝐮𝐬𝐞𝐝 𝐈𝐏 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲 and 𝐬𝐭𝐫𝐨𝐧𝐠 𝐬𝐮𝐩𝐩𝐥𝐲 𝐜𝐡𝐚𝐢𝐧 𝐜𝐚𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬, ensuring high-quality, timely product launches. Click here to find out more - https://lnkd.in/eqnxNkxz #Adalvo #AlwaysOnTarget #ValueAddedMedicine #Lisdexamfetamine #OralSolution #ProductLaunch
Adalvo Launches First-to-Market Lisdexamfetamine OS in Germany
adalvo.com
-
This week is #VAMweek and Adalvo joins the conversation on the 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐯𝐞 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐯𝐚𝐥𝐮𝐞 𝐚𝐝𝐝𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 (𝐕𝐀𝐌𝐬) in improving patient care. Just weeks ago at #CPHImilan, 𝐀𝐝𝐚𝐥𝐯𝐨 𝐫𝐞𝐜𝐞𝐢𝐯𝐞𝐝 𝐭𝐡𝐞 𝐕𝐚𝐥𝐮𝐞 𝐀𝐝𝐝𝐞𝐝 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐈𝐧𝐢𝐭𝐢𝐚𝐭𝐢𝐯𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐘𝐞𝐚𝐫 𝐚𝐰𝐚𝐫𝐝, a recognition of our commitment to developing differentiated solutions that address unmet medical needs. With a 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐯𝐚𝐥𝐮𝐞-𝐚𝐝𝐝𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐩𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨, Adalvo remains 𝐟𝐨𝐜𝐮𝐬𝐞𝐝 on simplifying treatments and delivering 𝐛𝐞𝐭𝐭𝐞𝐫 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬 for patients worldwide. #Adalvo #AlwaysOnTarget #ValueAddedMedicines
-
-
At Adalvo, it’s our people who 𝐦𝐚𝐤𝐞 𝐚𝐥𝐥 𝐭𝐡𝐞 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞. Today, we’re shining a light on Martina Feitzinger, recently appointed as our 𝐃𝐞𝐩𝐮𝐭𝐲 𝐂𝐄𝐎, 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐀𝐟𝐟𝐚𝐢𝐫𝐬. Martina shares her journey at Adalvo, the impact of her role, and her passions outside of work. #Adalvo #EmployeeSpotlight #LifeAtAdalvo
-
Adalvo has submitted the 𝐃𝐂𝐏 𝐟𝐨𝐫 𝐏𝐚𝐥𝐛𝐨𝐜𝐢𝐜𝐥𝐢𝐛 film-coated tablets on Day 1, following the 𝐞𝐱𝐩𝐢𝐫𝐲 𝐨𝐟 𝐃𝐚𝐭𝐚 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐢𝐭𝐲. Approval is expected in 2025. Supported by Adalvo’s 𝐟𝐨𝐜𝐮𝐬𝐞𝐝 𝐈𝐏 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲, this submission is part of Adalvo’s aim to address the global demand for advanced cancer treatments. Click here to find out more - https://lnkd.in/e3gbPnBq #Adalvo #AlwaysOnTarget #DCPsubmission #Palbociclib #Oncology
-
-
Adalvo wishes a 𝐇𝐚𝐩𝐩𝐲 𝐓𝐡𝐚𝐧𝐤𝐬𝐠𝐢𝐯𝐢𝐧𝐠 to our U.S.-based partners and friends! On this 𝐝𝐚𝐲 𝐨𝐟 𝐠𝐫𝐚𝐭𝐢𝐭𝐮𝐝𝐞, we reflect on the 𝐭𝐫𝐮𝐬𝐭 𝐚𝐧𝐝 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 that define our journey together. Wishing you and your loved ones a meaningful day 𝐟𝐢𝐥𝐥𝐞𝐝 𝐰𝐢𝐭𝐡 𝐰𝐚𝐫𝐦𝐭𝐡 𝐚𝐧𝐝 𝐜𝐨𝐧𝐧𝐞𝐜𝐭𝐢𝐨𝐧. #Thanksgiving #Adalvo #AlwaysOnTarget
-